Survodutide vs Retatrutide
Dual GLP-1/glucagon against the triple agonist that adds GIP.
The short answer: Both act on glucagon and GLP-1; only retatrutide also targets GIP.
Survodutide
Retatrutide
Side by side
| Property | Survodutide | Retatrutide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 5mg vial | 4mg × 4 pens |
| Dosage options | 5mg · 10mg | 4mg × 4 pens · 8mg × 4 pens · 12mg × 4 pens |
| Approved medicine using it | None — investigational | None — investigational |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €324.90 | €357.90 |
How they differ
Survodutide is a dual GLP-1 and glucagon receptor agonist. Retatrutide targets those same two receptors and adds GIP, making it the more complete of the two mechanistically.
That makes this the cleanest pairing in the catalogue for isolating the GIP contribution: the two compounds are otherwise mechanistically similar, so the difference between them is largely attributable to that third receptor.
Both remain investigational, and neither has a marketed brand.
At the bench
Both are investigational, so neither has an approved reference product to anchor against. Published dose ranges come from trial protocols rather than labelling, and those ranges move as the programmes progress.
What this comparison does not settle
Isolating the GIP contribution by comparing these two assumes everything else is equal, and it is not: the molecules differ in structure and in relative affinity at the receptors they do share.
Common questions
What is the difference between Survodutide and Retatrutide?
Both act on glucagon and GLP-1; only retatrutide also targets GIP. Dual GLP-1/glucagon against the triple agonist that adds GIP.
Is Survodutide or Retatrutide better?
Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Isolating the GIP contribution by comparing these two assumes everything else is equal, and it is not: the molecules differ in structure and in relative affinity at the receptors they do share.
Which of the two has more published data?
Neither has an approved formulation — both are investigational, and the published work on each is correspondingly narrower.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.